ORAGENICS INC
OGENNYSE AMERICANTrading Snapshot
- Day Range
- $0.47 – $0.48
- 52-Week Range
- $0.46 – $9.60
- Volume
- $3.18B
- Avg Volume
- $2.51B
- Shares Outstanding
- 4.5M
- Next Earnings
- Nov 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $474,056
- Last Q Revenue
- $120,066
- P/E Ratio
- -0.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.28
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −35.5%
Why Investors Own OGEN
- ✓High-growth profile — revenue up +54.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ORAGENICS INC
OGEN
StockOtter · stockotter.spaceAbout ORAGENICS INC
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platf
Oragenics (NYSEAMERICAN:OGEN) Trading Up 0.2% – Time to Buy?
Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) traded up 0.2% on Tuesday. The stock traded as high as $0.5490 and last traded at $0.5489. 31,024 shares changed hands during mid-day trading, an increase o
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
Company also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three Australian Phase IIa trial sites — Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital — are now active and